

## **Appendix 1. Included STOPP criteria**

### **Cardiovascular System**

Digoxin at a dose of >125mcg/day  
Thiazide with gout  
Non-cardioselective beta-blocker with chronic obstructive pulmonary disease (COPD)  
Beta-blocker with verapamil  
Aspirin & warfarin without histamine-2 receptor antagonist/proton pump inhibitor (PPI)  
Dipyridamole as monotherapy for cardiovascular prevention  
Aspirin at a dose of >150mg/day

### **Central Nervous System**

Tricyclic antidepressant with dementia  
Tricyclic antidepressant with glaucoma  
Tricyclic antidepressant with opiate/calcium channel blocker  
Long-term (>4 weeks) benzodiazepines  
Long-term (>4 weeks) neuroleptic  
Long term neuroleptic in those with parkinsonism  
Phenothiazines in those with epilepsy  
Anticholinergic with neuroleptic medications  
Prolonged use (>1 week) of first generation antihistamines

### **Gastrointestinal System**

Prochlorperazine/metoclopramide with parkinsonism  
PPI at max dosage for >8 weeks

### **Respiratory System**

Theophylline as monotherapy for COPD  
Nebulised ipratropium with glaucoma

### **Musculoskeletal System**

Long-term use (>3 months) of non-steroidal anti-inflammatory drug (NSAID)  
Warfarin and NSAID together

### **Urogenital System**

Antimuscarinic drugs with dementia  
Antimuscarinic drugs with chronic glaucoma

### **Endocrine System**

Glibenclamide/chlorpropamide for type 2 diabetes mellitus

### **Duplicate drug classes**

Duplicate antidepressants  
Duplicate SSRIs  
Duplicate opiates  
Duplicate NSAIDs  
Duplicate loop diuretics  
Duplicate ACE inhibitors